Background: Therapeutic drug monitoring of antiepileptic drugs (AEDs) is often necessary to prevent associated destructive toxicities. Tandem mass spectrometry (MS/MS) with stable-isotopelabeled internal standards is considered the gold standard for the measurement of AEDs. This study presents the development and validation of a clinical ultra-performance liquid chromatography-MS/MS method for the concurrent measurement of gabapentin, lamotrigine, levetiracetam, monohydroxy derivative of oxcarbazepine, and zonisamide in human serum.
INTRODUCTION
Worldwide, approximately 50 million people live with epilepsy and about one-quarter of this population is treated with antiepileptic drugs (AEDs). 1 Although newer generation AEDs such as gabapentin (GBP), lamotrigine (LTG), levetiracetam (LEV), oxcarbazepine (OXC), and zonisamide (ZNS) may offer better safety profiles compared with older ones, they can still result in rare but destructive toxicities associated with use, including hematopoietic dysfunction, pruritus, rash, Stevens-Johnson syndrome, anxiety, agitation, suicidal ideation, hepatic failure, gastrointestinal issues, and neurologic dysfunction. 2 Dosing these medications in the absence of therapeutic drug monitoring (TDM) can be challenging due to the narrow therapeutic ranges associated with these drugs, namely: GBP, 2-20 mcg/mL; LTG, 3-14 mcg/mL; LEV, 12-46 mcg/mL; OXC, 3-35 mcg/mL; and ZNS, 10-40 mcg/mL. 3 Compounding this difficult task is the significant variability between individuals in rates of excretion for LEV and rates of metabolism for ZNS, OXC, and LTG. 4 When treatment is suboptimal, especially in adolescent groups, therapeutic compliance may need to be assessed. In addition, some epileptic patients may have complex medical issues requiring several medications; therefore, drug-drug interactions are a common source of altered serum concentrations of AEDs. Although significant research has been devoted to AED biomarkers that predict therapeutic response, determination of AED serum levels is the first-line testing on medication complications. 5 Therefore, TDM of AEDs is often necessary to adequately and safely treat these patients.
Numerous methodologies have been developed for the measurement of AED levels in patient samples (see Table 1 , Supplemental Digital Content 1, http://links.lww.com/TDM/ A243). The preferred method for AED TDM is liquid chromatography-tandem mass spectrometry (LC-MS/MS) using stable-isotope-labeled internal standards (ISs). There are several considerations and competing factors to consider for implementation of a clinical TDM assay, including sensitivity, analytical measuring range (AMR), turnaround time, specimen volume (especially in pediatric populations), technical complexity, cost effectiveness, and clinical laboratory operations. We reviewed over 50 published methods developed to measure AEDs, and only 11 use ultra-performance liquid chromatography-tandem mass spectrometry (U-HPLC-MS/ MS), which can dramatically improve analytical run times without sacrificing peak resolution (see Table 2 , Supplemental Digital Content 2, http://links.lww.com/TDM/A244). [6] [7] [8] [9] [10] [11] [12] [13] In addition, none of these reported U-HPLC methods are able to measure GBP, LTG, LEV, OXC, and ZNS simultaneously. 14, 15 These 5 drugs/metabolites are the most frequently ordered AEDs for TDM at our institution. A multiplexed approach to measuring GBP, LTG, LEV, OXC, and ZNS would not only reduce costs by in-sourcing tests but would also offer operational efficiencies by being able to batch orders for any drug level into one run. Therefore, we sought to develop a U-HPLC-MS/MS method that could be easily implemented in a clinical laboratory at a tertiary academic medical center, with an emphasis on maintaining simplicity, low costs, and operational efficiency. Here, we present the validation of a rapid U-HPLC-MS/MS method for the simultaneous measurement of GBP, LTG, LEV, monohydroxy derivative (MHD) of OXC (the main, active OXC metabolite, also known as licarbazepine), and ZNS in serum.
MATERIALS AND METHODS

Materials
Water was obtained using a Milli-Q ultrafiltration system (.18.2 МV-cm resistivity), MilliporeSigma (Burlington, MA). Optima grade isopropanol (IPA), acetonitrile (ACN), formic acid, and methanol (MeOH) were purchased from Fisher Chemical (Pittsburgh, PA). GBP, GBP-D 10 , LTG, LTG-13 C, 15 N 4 , LEV, LEV-D 6 , (6)-10,11-dihydro-10-hydroxycarbamazepine (MHD), (6)-10,11-dihydro-10-hydroxycarbamazepine (MHD)-13 C 6 , ZNS, and ZNS-13 C 6 were acquired from Cerilliant Corporation (Round Rock, TX) (see Figure 1 , Supplemental Digital Content 3, http://links. lww.com/TDM/A242). All other reagents were used without further purification and from commercial suppliers.
Sample Preparation
On receipt, standards were stored at 2808C as recommended by the manufacturer. IS protein precipitation stock solution was prepared in ACN at the following final concentrations and stored at 2808C until used, undergoing only one freeze-thaw cycle: GBP-D 10 (1 mcg/mL), LTG-13 C, 15 N 4 (1 mcg/mL), LEV-D 6 (1 mcg/mL), (6)-10,11-MHD- 13 C 6 (1 mcg/mL), and ZNS-13 C 6 (1 mcg/mL).
Discarded serum samples were obtained according to an approved institutional review board protocol. AEDnegative serum was identified by U-HPLC-MS/MS analysis, pooled, and used to prepare calibrator and quality control (QC) samples. Calibration standards were prepared at the following concentrations: 0, 0.1, 0.5, 1, 5, 20, 50, and 100 mcg/mL. QC standards were prepared at the following concentrations: 0.1 mcg/mL (lower limit of quantification, LLOQ), 0.3 mcg/mL (low), 30 mcg/mL (mid), and 85 mcg/ mL (high). Calibration, QC serum samples, and IS protein precipitation solution were stored at 2808C and then thawed at room temperature for use, undergoing only 1 freeze-thaw cycle unless otherwise noted. Twenty microliters of the serum sample was pipetted into 100 mL of protein precipitation solution (ACN with 1 mcg/mL of each IS), vortex mixed for 10 seconds, and then clarified by centrifugation (20,800g) for 10 minutes. In a PFTE vial, 10 mL of the supernatant was then diluted into 90 mL of Milli-Q filtered water, vortexed for 10 seconds, and then placed into the autosampler, which was maintained at 158C. Samples were injected in 10 mL volumes per run for analyte quantification.
Analyte Separation and Quantification
The U-HPLC system consisted of a Waters (Milford, MA) ACQUITY UPLC I-Class System with a high-pressure binary pump, autosampler, column oven, and a flow-through needle for injections. Chromatography was performed using a reverse-phase Waters ACQUITY UPLC BEH C18 Column (2.1 · 30 mm, 1.7 mm particle size), which was maintained at 458C. The 2 mobile phases consisted of solvent A (2 mmol/L ammonium acetate in Milli-Q filtered water with 0.1% formic acid) and solvent B (2 mmol/L ammonium acetate in MeOH with 0.1% formic acid). The flow rate was 0.5 mL/min. Solvent B gradient conditions were as follows: initially set to 2% for 0.10 minutes, linear gradient from 2% to 12% for 0.05 minutes, sustained at 12% for 0.35 minutes, linear gradient from 12% to 50% for 1 minute, linearly raised to 99% over 0.1 minutes, continued at 99% for 0.6 minutes, lowered linearly to 2% over 0.1 minutes, and continued at 2% for 0.7 minutes, for a total run time of 3.0 minutes. The syringe and flow-through needle were cleaned between runs using a strong and a weak wash (1:1:1:1 Milli-Q filtered water/MeOH/IPA/ ACN v/v/v/v and 9:1 Milli-Q filtered water:ACN vol/vol, respectively).
MS analysis was performed in the positive electrospray ionization mode and collision-induced dissociation MS/MS on a Waters Xevo TQD tandem quadrupole mass spectrometer. Precursor-product ion transitions, retention time, cone voltage, and collision energy were optimized for each analyte and IS (Table 1 ). The following flow-dependent parameters were used: desolvation temperature, 6508C; desolvation gas flow, 1000 L/h; capillary voltage, 3.5 kV; source temperature, 1508C; cone gas flow, 0 L/h; extractor, 3.0 V; and RF lens, 2.5 V. Drug levels were quantified from the most abundant and reliable product ion for each analyte using MassLynx version 4.1 (version SCN855, Waters).
METHOD VALIDATION
This assay was validated in accordance with the guidelines published by the Food and Drug Administration (FDA): Guidance for Industry, Bioanalytical Method Validation. 16 
Calibration Curve Analysis and LLOQ
Analyte calibrators, as previously described, spanning 0.1-100 mcg/mL were assayed at the beginning and end of each experimental run and calibration curves were created using a 1/x 2 -weighted linear regression. The linearity of the calibration curve was assessed by averaging 3 independent runs. The LLOQ was established by meeting the FDAsuggested attributes of a coefficient of variation (CV) #20% and an inaccuracy of # 620% during the validation process.
Imprecision, Inaccuracy, and Carryover
Imprecision was assessed by calculating the percent coefficient of variation (% CV) and inaccuracy was determined by calculating the percent deviation (% DEV) from the theoretical concentration. Measurements for both parameters were performed at 4 QC levels (LLOQ, low, mid, and high) for each analyte, assessing intraday (n = 6) and interday characteristics (3 independent runs, total n = 18). Carryover was evaluated according to guidelines in CLSI document EP10-A2 by injecting high (85 mcg/mL) and low (0.1 and 0.3 mcg/mL) analyte samples in the following order: L1, L2, L3, H1, H2, L4, H3, H4, L5, L6, L7, L8, H5, H6, L9, H7, H8, L10, H9, H10, and H11. 17 Potential increases in the low sample values were analyzed by EP Evaluator release 9 (Data Innovations, South Burlington, VT).
Stability
Stability was performed at 4 QC levels (LLOQ, low, mid, and high) for each analyte using 4 technical replicates, assessing percent difference (% DIF) between freshly made QCs and the following conditions: QC samples left at room temperature (RT) for 24 hours before processing, QC samples that underwent 3 freeze-thaw cycles between RT (208C) and 2808C before processing, QC samples left at 2808C for 32 days before processing, and processed QC samples left in the autosampler for 24 hours at 158C. Analytes were considered stable when the % DIF was # 615%.
Matrix Effects, Recovery Efficiency, and Processing Efficiency
Matrix effects (ME), recovery efficiency, and processing efficiency were assessed at 3 QC levels (low, mid, and high) by spiking each analyte into 6 specimens of drug-free pooled human serum before and after protein precipitation and comparing with neat specimens, in which drugs were spiked into 30% ACN/H 2 O (vol/vol) before protein precipitation. Percent results were determined by comparing the ratio of analyte to IS raw peak areas between the following groups: ME, postprecipitated spiked serum to spiked ACN/H 2 O; recovery efficiency, preprecipitated spiked serum to postprecipitated spiked serum; and processing efficiency, preprecipitated spiked serum to spiked ACN/H 2 O. 18 
METHOD COMPARISON
Ten patient samples for each drug were obtained from Mayo Medical Laboratories (Rochester, MN), which used an LC-MS/MS method for analyte quantification. Comparison between methodologies was accomplished using Deming regression using GraphPad Prism 7.0 (GraphPad Software, La Jolla, CA).
RESULTS
Empirical Determination of Assay Range
To guide our assay parameters, we analyzed AED level results in our patient population measured at a national reference laboratory for a period of one year (Fig. 1 ). The average GBP serum level was 7.0 6 4.4 mcg/mL (n = 23), with 2 samples falling below the LLOQ of 0.5 mcg/mL. For LTG, the average serum level was 6.9 6 4.5 mcg/mL (n = 902), with 17 samples falling below the LLOQ of 0.2 mcg/ mL. The average LEV serum level was 26.2 6 17.0 mcg/mL (n = 538), with 43 samples falling below the LLOQ of 2.0 mcg/mL. MHD had an average serum level of 18.3 6 8.5 mcg/mL (n = 162), with 10 samples falling below the LLOQ of 1.0 mcg/mL, and the average ZNS serum level was 17.9 6 10.1 mcg/mL (n = 111), with 17 samples falling below the LLOQ of 1.0 mcg/mL. Therefore, an assay range of 0.1-100 mcg/mL was subsequently chosen for all analytes.
Optimization of U-HPLC-MS/MS Method
The C18 U-HPLC method was optimized to give maximum separation between analytes to increase the per analyte dwell time, while simultaneously achieving a 3-minute total analytical run time, including equilibration of the column (Fig. 2) . All analytes eluted between 0.92 and 1.68 minutes. MS parameters that achieved the greatest sensitivity of the AEDs were determined (Table 1) .
Imprecision, Inaccuracy, and Linearity
Intraday and interday inaccuracy were within the acceptable ranges per FDA bioanalytical guidelines for all levels of QC (% DEV # 620 for the LLOQ and % DEV # 615 for low, mid, and high QC, Table 2 ). Likewise, intraday and interday imprecision were also within the acceptable ranges per the FDA bioanalytical guidelines for all levels of QC (% CV #20 for the LLOQ and % CV #15 for low, mid, and high QC, Table 2 ). All analytes measured were linear within the AMR with R 2 values ranging from 0.9988 to 0.9999 (Table 2 ).
Stability and Carryover
Sample stability was assessed by comparing fresh QC samples and samples that were exposed to various temperatures. All analytes were stable at RT for 24 hours (% DIF #15), except for the LLOQ concentration (0.1 mcg/mL) for ZNS (Table 3 ). All analytes were also stable for 3 freezethaw cycles (280-208C defining one cycle), except for MHD at the mid level (15.27%) and ZNS at mid and high levels (16.33, 15.33%, Table 3 ). Finally, all analytes were stable at 2808C for 32 days and for 24 hours at 158C in the autosampler (Table 3) .
GBP, LEV, and MHD demonstrated acceptable levels of carryover between a high and low sample (85-0.1 mcg/ mL), whereas ZNS and LTG exhibited carryover at the 85-0.1 mcg/mL levels, but did not at the 85-0.3 mcg/mL levels (data not shown). Therefore, when this method is being used to measure unknown samples, ZNS and LTG samples that have concentrations ,0.3 mcg/mL should be repeated if they were preceded by a sample with a high drug level.
Selectivity and MEs
Selectivity was assessed by analyzing pooled human serum for endogenous metabolites corresponding to the same retention times and ion mass transitions as the AEDs measured in this study. The chromatogram of the pooled serum did not demonstrate any corresponding peaks; therefore, this assay is highly selective for the measured analytes (data not shown). MEs were calculated and are summarized in Table 4 . Although all the analytes demonstrate varying degrees of ion suppression, the difference between the IS and analytes is #10% and therefore, the ISs behave in a similar fashion. This assay functions well for accurately quantifying AEDs.
METHOD COMPARISON
Ten samples per drug (50 in total) were obtained from a national reference laboratory, which measured the drug levels by LC-MS/MS. These values were compared with the drug levels measured by the described U-HPLC-MS/MS method (Fig. 3) . Using Deming regression for analysis, R 2 (and slopes) of 0.99 (1.17), 0.99 (0.89), 0.99 (1.05), 0.99 (1.03), and 0.99 (1.04) were calculated for GBP, LTG, LEV, MHD, and ZNS, respectively. These results demonstrate that the 2 methods show an acceptable concordance.
DISCUSSION
The validated U-HPLC-MS/MS method described herein simultaneously measures human serum drug levels for GBP, LTG, LEV, MHD, and ZNS over the range of 0.1-100 mcg/mL. It improves on previously reported methodologies because this is the first report of a multiplex AED TDM assay of these drugs that uses isotopic standards for each analyte (see Tables 1 and 2 , Supplemental Digital Content 1 and 2, http://links.lww.com/TDM/A243, http://links.lww. com/TDM/A244, respectively). In addition, we simultaneously achieved shorter run times, smaller sample volumes, and a wider AMR than most of the methodologies published. Most importantly, we purposely optimized this assay for qualities desired by a typical hospital laboratory, balancing speed, workflow simplicity, and operational throughput while minimizing reagent and labor costs. 19 We established a suitable AMR for our patient population by analyzing 1 year of AED TDM results. Taking into account all analytes in the panel, the lowest measured therapeutic range value was 2 mcg/mL (GBP) and our highest was 46 mcg/mL (LEV). From our analysis of 1 year of AED TDM values, 4.9% (89/1825) of AED serum values were below the reference laboratory's reportable range. To maximize information to clinicians for dosing adjustment changes and minimize retesting required for diluting samples above our reported range, we chose to develop an assay with an AMR from 0.1 to 100 mcg/mL.
We also recognized that clinicians at our institution would benefit tremendously from a fast turnaround time to rapidly manage patients with toxic and subtherapeutic drug levels. We were able to minimize assay time by implementing a 1-step protein precipitation with ACN and designing a U-HPLC method that allows for a 3-minute total run time, which GBP  106  98  95  105  100  103  LTG  105  106  91  97  95  104  LEV  100  106  100  96  100  102  MHD  104  104  97  98  101  102  ZNS  104  103  101  99  106  102 includes column reequilibration. An additional advantage of this assay is that it only requires 20 mL of sample volume; this enables testing on neonatal and pediatric populations and reduces reagent costs. As a clinical laboratory at a tertiary academic medical center, one of our main goals was to develop a cost-effective assay. Therefore, we used the same liquid chromatography system as the assays already implemented in the laboratory to maximize use of common reagents and standard operating procedures. We also chose to prepare our samples using a rapid protein precipitation protocol to decrease the complexity and hands-on time for this assay. By multiplexing 5 analytes into 1 assay, staffing requirements are reduced to 1 station, which minimizes labor expenses. Finally, by establishing an in-house assay, we are now able to save on reference laboratory send out costs.
Although our method has many advantages, it has a few limitations as well. U-HPLC-MS/MS instrumentation has a relatively high capital cost; however, with the significant improvements on throughput due to shortened run times, clinical laboratories can establish more TDM assays on the same equipment compared with LC systems. In addition, this methodology is adaptable to LC-MS/MS systems. To balance need with reagent costs, we specifically chose the 5 highest volume AED analytes for our patient population that were amenable to electrospray ionization positive ion mode MS. Therefore, other AED TDM requests would have to be sent to reference laboratories. Finally, although we used isotopes of all the analytes as ISs to compensate for the minimally observed MEs, the deuterated drug analogs had a slightly shorter retention time compared with their nondeuterated counterparts, which is a well-known phenomenon. 20 On commercial availability, use of 13 C and 15 N isotopes of LEV and GBP as ISs could further minimize potential MEs.
CONCLUSIONS
We have developed and validated a cost-effective, robust, simple, and rapid U-HPLC-MS/MS method for TDM of common AEDs in human serum. We expect that this method can be implemented in clinical laboratories performing mass spectrometry.
